TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07081997: A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

Sponsor: Ascendis Pharma Bone Diseases A/S · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 36 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,791,472

Rescue Site Savings

+$1,178,600

Unlock Full NCT07081997 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07081997 Rescue Dossier →